Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

AJ (Diane) van der Biessen, Merlijn Cranendonk, Gaia Schiavon, Ronnie van der Holt, Erik Wiemer, Ferry Eskens, Jaap Verweij, Maja de Jonge, RHJ Mathijssen

Research output: Contribution to journalArticleAcademic

17 Citations (Scopus)

Abstract

Introduction. For anticancer drug development, it is crucial that patients participate in early-phase clinical trials. The main aim of this study was to gain insight into the motivations and other variables influencing patients in their decision to participate in phase I oncology trials. Materials and Methods. Over a period of 25 months, all patients who were informed about (specific) phase I trials in our cancer center were retrospectively included in this study. Data on providing informed consent and final phase I enrollment were collected. Results. In total, 365 patients, with a median age of 59 years and a median World Health Organization performance status score of 1, were evaluated. The majority of patients (71%) were pretreated with systemic therapy, with a median of two lines. After specific study information had been given, 145 patients (40%) declined informed consent, 54% of them mainly because of low expectations regarding treatment benefits and concerns about potential side effects. Patients who had received previous syst Discussion. After specific referral to our hospital for participation in early clinical trials, only 44% of all patients who were informed about a specific phase I trial eventually participated. Reasons for both participation and nonparticipation were diverse. Patient participation rates could be improved by forming an experienced and dedicated study team. The Oncologist 2013;18:323-329
Original languageUndefined/Unknown
Pages (from-to)323-329
Number of pages7
JournalOncologist
Volume18
Issue number3
DOIs
Publication statusPublished - 2013

Cite this